CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $269.6M, lower than 95% of all stocks globally
- PositionGross margin is 6.1%, lower than 95% of its Biotechnology peers (median 67.2%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.81BCNY269.60M · vs all stocks (USD)
Revenue (TTM)
136.13MCNY20.32M · vs all stocks (USD)
Profit Margin
-98.48%vs Biotechnology peers
Beta
0.2380xvs all stocks
52-Week Change
-44.42%vs all stocks
Market Capitalization
1.81BCNY269.60M · vs all stocks (USD)
Enterprise Value
1.39BCNY208.18M · vs all stocks (USD)
Price to Sales (TTM)
12.99xvs Biotechnology peers
Price to Book (MRQ)
2.28xvs Biotechnology peers
Enterprise to Revenue
10.25xvs Biotechnology peers
Enterprise to EBITDA
-22.16xvs Biotechnology peers
Gross Margin
6.12%vs Biotechnology peers
Profit Margin
-98.48%vs Biotechnology peers
Operating Margin
-79.74%vs Biotechnology peers
Return on Assets (TTM)
-6.11%vs Biotechnology peers
Return on Equity (TTM)
-19.01%vs Biotechnology peers
Revenue (TTM)
136.13MCNY20.32M · vs all stocks (USD)
Revenue per Share (TTM)
0.4960CNYUpdated Sep 22, 2026Quarterly Revenue Growth
41.30%vs Biotechnology peers
Gross Profit (TTM)
21.59MCNY3.22M · vs all stocks (USD)
EBITDA (TTM)
-62.95MCNY-9.40M · vs all stocks (USD)
Net Income (TTM)
-134.06MCNY-20.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
41.35%vs Biotechnology peers
Operating Cash Flow (TTM)
20.74MCNY3.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
2.75MCNY410.69K · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-71.14MCNYFY2025 · Dec 31, 2025Revenue
141.93MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
97.22MCNYFY2025 · Dec 31, 2025Gross Profit
44.71MCNYFY2025 · Dec 31, 2025Operating Income
-78.24MCNY-11.68M · vs all stocks (USD)
Pre-tax Income
-132.75MCNYFY2025 · Dec 31, 2025Income Tax Expense
17.01MCNYFY2025 · Dec 31, 2025Net Income
-149.75MCNYFY2025 · Dec 31, 2025EBIT
-129.17MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-38.98MCNYFY2025 · Dec 31, 2025Research & Development
35.36MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
49.97MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.58MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.4989CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.4989CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
274.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
274.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-149.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
12.85MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
77.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
2.32MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
296.37MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-149.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.62MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
178.32MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
45.37MCNYFY2025 · Dec 31, 2025Capital Expenditures
-75.24MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-75.24MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
10.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-219.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.71MCNYFY2025 · Dec 31, 2025Other Financing Charges
-21.52MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-233.23MCNYFY2025 · Dec 31, 2025Shares Outstanding
274.40MSharesUpdated Sep 22, 2026Float Shares
148.29MSharesUpdated Sep 22, 2026% Held by Insiders
48.27%vs all stocks
% Held by Institutions
1.59%vs all stocks
Total Cash (MRQ)
347.18MCNY51.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.28CNYUpdated Sep 22, 2026Total Debt (MRQ)
60.02MCNY8.96M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0846xvs Biotechnology peers
Current Ratio (MRQ)
3.13xvs Biotechnology peers
Book Value per Share (MRQ)
2.84CNYUpdated Sep 22, 2026Total Assets
809.47MCNY120.83M · vs all stocks (USD)
Total Current Assets
399.83MCNYFY2025 · Dec 31, 2025Total Liabilities
97.06MCNYFY2025 · Dec 31, 2025Total Non-current Assets
409.64MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
3.54MCNYFY2025 · Dec 31, 2025Total Current Liabilities
93.52MCNYFY2025 · Dec 31, 2025Cash
297.66MCNYFY2025 · Dec 31, 2025Cash Equivalents
3.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
301.52MCNYFY2025 · Dec 31, 2025Accounts Receivable
36.03MCNYFY2025 · Dec 31, 2025Inventory
35.88MCNYFY2025 · Dec 31, 2025Accounts Payable
27.23MCNYFY2025 · Dec 31, 2025Short-term Debt
10.03MCNYFY2025 · Dec 31, 2025Other Current Liabilities
10.64MCNYFY2025 · Dec 31, 2025Common Stock (Book)
274.40MCNYFY2025 · Dec 31, 2025Retained Earnings
-660.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
712.41MCNY106.34M · vs all stocks (USD)
Treasury Stock
26.14MCNYFY2025 · Dec 31, 202552-Week Low
5.47CNYUpdated Sep 22, 202652-Week High
12.06CNYUpdated Sep 22, 202652-Week Change
-44.42%vs all stocks
Beta
0.2380xvs all stocks
50-Day MA
6.75CNYUpdated Sep 22, 2026200-Day MA
7.72CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.12MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.87MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.4900CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 6.1%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 0.06Industry median: 0.67Industry P5: 0.14Peers compared: 260
Financial Health
Altman Z-Score 10.13: safe zoneNotable
Altman Z-Score: 10.13
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $269.6M, lower than 95% of all stocks globallySignificant
Market cap (USD): 269,601,132.574Global P5: 275,556,405.438
Revenue is $20.32M, lower than 95% of all stocks globallySignificant
Revenue (USD): 20,319,513.69Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Myson Century Inc.
2 interpretationsCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Guangdong Guangzhou Daily Media Co., Ltd.
2 interpretationsCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hunan Yujing Machinery Co., Ltd.
2 interpretationsCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated